The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of capecitabine combined with peginterferon alfa-2a in sorafenib-refractory advanced hepatocellular carcinoma patients.
Sadahisa Ogasawara
No relevant relationships to disclose
Tetsuhiro Chiba
No relevant relationships to disclose
Yoshihiko Ooka
No relevant relationships to disclose
Naoya Kanogawa
No relevant relationships to disclose
Tenyu Motoyama
No relevant relationships to disclose
Eiichiro Suzuki
No relevant relationships to disclose
Akinobu Tawada
No relevant relationships to disclose
Fumihiko Kanai
No relevant relationships to disclose
Osamu Yokosuka
Research Funding - Chugai Pharma